Lysosomal-Associated Transmembrane Protein 5 Promotes Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma

Figure 1

LAPTM5 expression is increased in patients with ccRCC and is associated with the stage and prognosis of ccRCC. (a) LAPTM5 is differentially expressed in numerous tumors, including ccRCC (statistical description of tumors are listed in Table S4 in the Supplementary Material). (b) and (c)Expression of LAPTM5 in tumor tissues and healthy tissues (GSE 6344 and GSE 781). (d) Expression of LAPTM5 in tumor tissues of patients with ccRCC and adjacent healthy tissues (tumor, n = 539; nontumor, n = 72) in TCGA. (e) Expression of LAPTM5 in paired tumor tissues and adjacent healthy tissues in patients with ccRCC (n = 72) in TCGA. (f) Expression of LAPTM5 in different TNM stages (T1 and T2, n = 349; T3 and T4, n = 190) in TCGA. (g) Overall survival curve of ccRCC with high and low LAPTM5 expression levels (high, top 30%, n = 179; low, bottom 30%, n = 178) in TCGA. (h) mRNA expression of LAPTM5 in ccRCC tissues and adjacent healthy tissues (n = 3 independent experiments), basic information of patients are listed in Table S5 in the Supplementary Material. (i) Western blot analysis of LAPTM5 in every group (n = 3 independent experiments). (j) Western blot analysis of LAPTM5 in every group (n = 3 independent experiments). fnlowast vs. nontumor or low, fnlowast vs. nontumor or low, fnlowast vs. nontumor or low. NS, not significant; abbreviation: LAPTM5, lysosomal-associated transmembrane protein 5; ccRCC, clear cell renal clear cell carcinoma; TCGA, The Cancer Genome Atlas; T2&T1: TNM stages II and I; T4&T3: TNM stages IV and III; Case 1–3: patients with ccRCC 1–3; T1–T3: tumor tissue of patient 1–3; N1–N3: nontumor tissue (adjacent tissue) of patient 1–3.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)